Genitourinary Drugs Market Analysis- Size, Share, Growth, Trends and Forecasts, 2015 To 2022: Grand View Research

Global genitourinary drugs market is anticipated to witness remarkable growth over the coming seven years due to increasing prevalence of urinary disorders and related illness. In addition, technological upgradations in genitourinary devices and growing concerns pertaining to impotency & urinary incontinence are some factors expected to propel the growth of genitourinary drugs market in near future.

Request to Sample of This Report @ http://www.grandviewresearch.com/industry-analysis/genitourinary-drugs-market

The global genitourinary drugs market is divided on the basis of product and disease. By products, the market is segmented into sex hormones, gynaecologicals, urologicals and genitourinary anti infectives. The genitourinary anti invectives’ market is anticipated to register fastest growth over the forecast period due to rising prevalence of urinary tract diseases. By disease, the market is divided into renal cancer, ovarian cancer, cervical cancer, prostate cancer, bladder cancer and genitourinary cancer. Regionally, as of 2014, North America witnessed highest market growth owing to technological advancements, favourable government policies and increasing incidences of urinary cancer. Improving healthcare awareness and increasing geriatric population base is expected to result in rapid market growth in European region. Asia pacific region is expected to witness fastest market growth over the coming seven years owing to increasing usage of effective medications, rise in personal disposable income and increasing incidence rate of urinary cancer and related disorders. Similarly, Latin American region is anticipated to register speedy growth over the forecast period due to revamped healthcare infrastructure and availability of exhaustive & cost effective drugs in this region.

The prominent players operating in global genitourinary drugs market are Merck Serono S.A., Teva Pharmaceuticals Inc., Allergan Inc., Abbott Laboratories, Hoffman La Roche, GlaxoSmithKline, Watson Pharmaceuticals Inc., Agile Therapeutics Inc., Bristol Myers Squibb, Kissei Pharmaceuticals Co. Ltd., Novo Nordisk A/S, PregLem S.A., VIVUS Inc., Isis Pharmaceuticals and Recordati S.p.A. The companies are entering into mergers, R&D activities and product modification processes to increase their market share. For example, in 2013, Allergan Inc. received FDA approval for a drug namely BOTOX. The drug is mainly used for the treatment of overactive bladder resulting in leakage, sudden urge to go and going too often. Also in 2012, Detrol LA introduced anticholinergic drug that block nerves controlling bladder muscles and allows for relaxation of muscles. These drugs also helps control the urge of urinary incontinence.

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.

For More Information, Visit Grand View Research

Contact:

Sherry James

Corporate Sales Specialist, U.S.A.

Grand View Research, Inc.

United States

Phone: 1-415-349-0058

Toll Free: 1-888-202-9519

Email: sales@grandviewresearch.com

Blog Site: http://www.mediafound.org/